Patent ID: 9188595
Filing Date: 2015-11-17
Classification: A61K,A61P,G01N

Abstract:
1. A method of diagnosing Alzheimer's disease in an individual, the method comprising: (a) contacting cells from the individual and from a non-Alzheimer's control subject with at least one inhibitor chosen from BiSM-1, PP1, 2-aminoethoxydiphenyl borate, and LY-294002; (b) contacting cells from the individual and from the non-Alzheimer's control subject with at least one agent that triggers intracellular calcium release via the inositol 1,4,5-trisphosphate (IP-3) receptor, wherein the at least one agent is chosen from bradykinin, a bradykinin receptor agonist, and bombesin; (c) measuring the amount of phosphorylation of at least one mitogen activated protein kinase (MAPK) protein in the individual's cells and in the non-Alzheimer's control subject's cells at one or more time points, and comparing the amount of phosphorylation of the at least one MAPK protein in the individual's cells with the amount of phosphorylation of the MAPK protein in the cells from the non-Alzheimer's control subject at the same one or more time points; wherein increased phosphorylation of the at least one MAPK protein in the individual's cells compared to the non-Alzheimer's control subject's cells is indicative of Alzheimer's disease, wherein the one or more time points are chosen from about 0.5 minutes, about 1 minute, about 2 minutes, about 2.5 minutes, about 5 minutes, about 10 minutes, about 20 minutes, and about 30 minutes after contacting the individual's cells and the non-Alzheimer's control subject's cells with the at least one agent.